Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clear Cell Renal Cell Carcinoma (ccRCC)
100%
Von Hippel-Lindau
100%
Genomic Landscape
100%
Advanced Renal Cell Carcinoma (aRCC)
100%
Landscape Studies
100%
Genetic Modification
85%
Microsatellite Instability-high (MSI-H)
28%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
28%
Low Positive
28%
PD-L1 Expression
28%
Tumor Protein p53 (TP53)
14%
Tumor Suppressor Gene
14%
Metastatic Disease
14%
Locoregional
14%
Drug Development
14%
BRCA1-associated Protein 1 (BAP1)
14%
Clinical Trial Design
14%
Cell Cycle Genes
14%
Selection Bias
14%
Pathway Genes
14%
CDKN2B
14%
Combination Strategy
14%
TSC1
14%
Sequence Data
14%
Female Gender
14%
Von Hippel-Lindau Disease
14%
Cyclin-dependent Kinase 4/6 Inhibitors
14%
PIK3CA
14%
Age Distribution
14%
NF-2
14%
Von Hippel-Lindau Tumor Suppressor
14%
Hybrid Capture
14%
Loco
14%
MTOR Pathway
14%
Tumor mutation Burden
14%
Dako
14%
PBRM1
14%
SETD2
14%
Immunotherapy Response
14%
Clinical Data Annotation
14%
Comprehensive Genomic Profiling
14%
Extremely Rare
14%
High Status
14%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Genetics
100%
Biological Marker
22%
Microsatellite Instability
22%
Cyclin Dependent Kinase Inhibitor 2A
22%
Programmed Death-Ligand 1
22%
Tumor Suppressor Gene
11%
Metastatic Carcinoma
11%
Cell Cycle
11%
Regulator Gene
11%
Clinical Trial Design
11%
Selection Bias
11%
Age Distribution
11%
Cyclin-Dependent Kinase 4
11%
Von Hippel-Lindau Tumor Suppressor
11%
Comprehensive Genomic Profiling
11%
Tumor Mutation Burden
11%
Immunotherapy Response
11%
Biochemistry, Genetics and Molecular Biology
Genomics
100%
Wild Type
100%
Microsatellite Instability
20%
PD-L1
20%
Cyclin Dependent Kinase Inhibitor 2A
20%
Tumor Suppressor Gene
10%
Cell Cycle
10%
BAP1
10%
CDKN2B
10%
TSC1
10%
Locus Control Region
10%
Cyclin-Dependent Kinase 4
10%
Von Hippel-Lindau Tumor Suppressor
10%
Clinical Trial Design
10%
Age Distribution
10%
PBRM1
10%
SETD2
10%
Drug Development
10%